Xanthomatous Eczema: A Complete Patient‑Friendly Guide

Overview

Xanthomatous eczema (also called “xanthoma‑type eczema” or “xanthomatous dermatitis”) is an uncommon form of inflammatory skin disease that combines features of classic eczema (atopic or contact dermatitis) with yellow‑orange, lipid‑laden papules or plaques that resemble xanthomas. The lesions often appear on the extremities, trunk, or flexural sites and may be itchy, scaly, or mildly painful.

Because the condition is rare, exact prevalence data are limited. Case series from dermatology centers suggest an incidence of roughly 1‑2 per 100,000 individuals worldwide, with a slight predominance in adults aged 30‑60 years. Both sexes are affected, though a modest female preponderance (≈55 %) has been reported in most series.

It is most frequently encountered in people with underlying lipid metabolism disorders (familial hypercholesterolemia, dysbetalipoproteinemia) or chronic inflammatory skin disease. However, idiopathic cases—where no systemic cause is identified—also occur.

Symptoms

The clinical picture is variable, but the following symptom spectrum is typical:

• Yellow‑orange papules or plaques – Soft, often well‑circumscribed, ranging from 2 mm to >1 cm.
• Itch (pruritus) – Frequently intense, leading to scratching and secondary infection.
• Scaling or crusting – May mimic classic eczematous dermatitis.
• erythema – Redness surrounding the xanthomatous lesions.
• Fever or malaise – Uncommon, usually only if secondary infection develops.
• Location – Commonly on elbows, knees, extensor surfaces, buttocks, and occasionally on the face.
• Texture change – Lesions can become firm or nodular over time (xanthoma‑like).
• Associated skin signs – Eczema in other body areas, such as flexural dermatitis, may coexist.

Causes and Risk Factors

Primary mechanisms

Xanthomatous eczema is thought to arise from a combination of:

1. Lipid accumulation in skin macrophages – Elevated serum lipids (especially triglyceride‑rich VLDL or chylomicrons) are taken up by dermal histiocytes, forming foam cells that give the lesions their yellow hue.
2. Inflammatory milieu of eczema – Barrier dysfunction and Th2‑dominant inflammation promote itch, scratching, and secondary lipid deposition.
3. Genetic predisposition – Mutations in genes governing lipid metabolism (e.g., APOB, LPL) increase susceptibility.

Risk factors

• Pre‑existing eczema or atopic dermatitis.
• Inherited lipid disorders – familial hypercholesterolemia, type III dysbetalipoproteinemia, familial combined hyperlipidemia.
• Obesity and metabolic syndrome – associated with higher serum triglycerides.
• Chronic liver disease or nephrotic syndrome – can cause secondary hyperlipidemia.
• Medications that raise lipid levels – e.g., retinoids, protease inhibitors.
• Smoking and excessive alcohol intake – both exacerbate lipid abnormalities.

Diagnosis

Because the disease mimics both eczema and xanthomas, a thorough evaluation is essential.

Clinical assessment

• Detailed history – onset, distribution, itching severity, family history of lipid disorders, medication use.
• Physical exam – inspection of lesion color, texture, and any associated eczematous changes.

Laboratory tests

• Lipid panel – total cholesterol, LDL‑C, HDL‑C, triglycerides; >200 mg/dL total cholesterol or >150 mg/dL triglycerides is common in affected patients.
• Blood glucose & HbA1c – to screen for diabetes, a common comorbidity.
• Liver function tests – to rule out hepatic contribution to hyperlipidemia.

Skin biopsy

When the diagnosis is uncertain, a 4‑mm punch biopsy is performed. Histopathology typically shows:

• Upper dermal infiltrate of foamy macrophages (xanthoma cells).
• Epidermal spongiosis and superficial perivascular lymphocytic infiltrate consistent with eczema.
• Absence of malignancy markers, helping to differentiate from cutaneous lymphoma.

Additional imaging (rare)

In cases with extensive systemic xanthomatosis, ultrasound or MRI may be ordered to evaluate tendons or internal organs, but this is uncommon for isolated skin disease.

Treatment Options

Management targets two fronts: controlling inflammation/itch and correcting underlying lipid abnormalities.

Topical therapies

• Low‑to‑mid potency corticosteroids (hydrocortisone 1 %–2.5 % or triamcinolone 0.1 %) applied twice daily for 2‑4 weeks to reduce acute inflammation.
• Calcineurin inhibitors (tacrolimus 0.1 % ointment or pimecrolimus 1 %) – useful for steroid‑sparing in delicate areas.
• Moisturizers & barrier repair creams – ceramide‑rich emollients applied 2‑3 times daily to restore skin barrier.
• Topical retinoids (tazarotene 0.05 %) – can promote turnover of foam cells, but may irritate; use under supervision.

Systemic medications

• Oral antihistamines (cetirizine, loratadine) – relieve itch, especially at night.
• Systemic corticosteroids – short courses (≤2 weeks) for severe flares; not for long‑term use due to side effects.
• Statins (atorvastatin, rosuvastatin) – first‑line for hyperlipidemia; can reduce lesion size by lowering circulating lipids.
• Fibrates** (gemfibrozil, fenofibrate) – adjunct for high triglycerides.
• Biologic agents – Dupilumab (IL‑4Rα antagonist) has shown benefit in refractory eczematous disease with a favorable effect on lipid metabolism in some case reports.
• Phototherapy – narrow‑band UVB 3‑5 times weekly can improve eczema and may aid in clearing xanthomatous plaques.